Medical Advocates
Atazanavir (Reyataz)
 
Perinatal Data

New and Noteworthy
 Treatment Guidelines
 Journal Data
 Conference Data




 

  
Atazanavir Main Page New/Newsworthy Home Page      
Last updated:  March 22, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
March 2012 2011
 
Treatment Guidelines
       
United States

          Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  PDF DOCUMENT
 Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
Journal Citations
       
  Monitoring the Risk of Birth Defects Associated with Atazanavir Exposure in Pregnancy.
 Esker S, Albano J, Uy J
AIDS Patient Care STDS. 2012 Mar 9.
 Abstract

Atazanavir and Atazanavir/Ritonavir Pharmacokinetics in HIV-Infected Infants, Children,
and Adolescents.
Kiser JJ, Rutstein RM, Samson P, et al
AIDS. 2011 May 21.
 Abstract

Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Mandelbrot L, Mazy F, Floch-Tudal C, et al
Eur J Obstet Gynecol Reprod Biol. 2011 Apr 12
 Abstract

FULL-TEXT ARTICLE
Atazanavir Pharmacokinetics With and Without Tenofovir during Pregnancy.
Mirochnick M, Best BM, Stek AM,  et al
J Acquir Immune Defic Syndr. 2011 Jan 28
 Paper

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
 Ripamonti D, Cattaneo D, Maggiolo F, et al 
AIDS. 2007 Nov 30;21(18):2409-2415.
 Abstract
Conference Citations
       
 
POSTER
 A Comparison of the Pharmacokinetics of Darunavir, Atazanavir, and Ritonavir during Pregnancy and Post-partum
A Colbers, J Molto, J Ivanovic, et al
 (19  CROI)
PDF Poster     Abstract

A Population Pharmacokinetic Model Illustrates an Association Between a Pregnane-X-Receptor
(PXR) Polymorphism and Boosted Atazanavir Clearance
 A Schipani, M Siccard, M Boffito, et al 
(17 CROI
 Abstract

POSTER
 The safety, efficacy, and steady state pharmacokinetics of atazanavir/ritonavir (ATV/r) once daily
given in combination with twice daily AZT/3TC during pregnancy: results of study AI424182
F. Conradie, C. Zorilla, D. Josipovic, et al  
(5th IAS Conference)
PDF Poster      Abstract

Necessity of intensive UV-phototherapy for atazanavir associated neonatal hyperbilirubinemia: a case report
 C. Ferreira, G. Morau, G. Peytavin,  et al
(XVII International AIDS Conference)
 Abstract
 
Pharmacokinetics and clinical outcomes with Atazanavir 300 mg QD/ritonavir 100 mg (ATV/r) QD + ZDV/3TC
during the 3rd trimester of pregnancy in HIV+ women: interim results from BMS AI424182
 T. Eley, E. Vandeloise, M. Child, et al    
 (XVII International AIDS Conference)
 Abstract
 
POSTER
 Atazanavir in Pregnancy: Influence on Neonatal Hyperbilirubinemia
C Ferreira, C Floch-Tudal, F Meier, et al
 (15th CROI)
 PDF Poster     Abstract
 
Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg
Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV+ Women
T Eley, E Vandeloise, M Child
(15th CROI)
 Abstract

POSTER
 Atazanavir Use in Pregnancy
 Morris A 
(3rd IAS Conference)
PDF Poster

Atazanavir Main Page New/Newsworthy Home Page      

Atazanavir Perinatal Data